• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma.
【24h】

Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma.

机译：复发性和难治性侵袭性非霍奇金淋巴瘤的治疗策略。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aggressive non-Hodgkin's lymphomas (NHL) are a clinically heterogeneous group of lymphomas with disparate responses to standard chemotherapy regimens. Aggressive NHL includes diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and peripheral T-cell lymphomas (PTCL), among others. Significant advances have been made in the last decade in the initial treatment of DLBCL and MCL, but the treatment of relapsed or refractory disease remains difficult. The addition of rituximab to the treatment of DLBCL and MCL has improved clinical outcomes and is now a critical component of initial therapy and treatment of relapsed disease. The PTCLs, not having a similar agent to significantly change the treatment approach to these diseases, remain a difficult therapeutic problem. This review examines recent advances in the treatment of relapsed or refractory aggressive NHL and discusses novel approaches currently under investigation.
机译：侵袭性非霍奇金淋巴瘤（NHL）是临床上异质性的一组淋巴瘤，对标准化疗方案的反应不同。侵略性NHL包括弥漫性大B细胞淋巴瘤（DLBCL），套细胞淋巴瘤（MCL）和周围T细胞淋巴瘤（PTCL）等。在过去的十年中，DLBCL和MCL的初始治疗取得了重大进展，但是复发或难治性疾病的治疗仍然很困难。在DLBCL和MCL的治疗中加入利妥昔单抗改善了临床疗效，现在已成为初始治疗和复发性疾病治疗的关键组成部分。 PTCLs没有类似的药物来显着改变对这些疾病的治疗方法，仍然是一个棘手的治疗问题。这篇综述审查了复发性或难治性侵袭性NHL治疗的最新进展，并讨论了目前正在研究的新方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号